Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
captopril + furosemide
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Captopril + furosemide is a combination of an angiotensin-converting enzyme (ACE) inhibitor and a loop diuretic used to treat hypertension and heart failure. Captopril works by inhibiting the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and blood pressure. Furosemide acts on the kidneys by inhibiting sodium-potassium-chloride cotransporters in the ascending loop of Henle, increasing water and electrolyte excretion. The combination provides additive blood pressure lowering effects but requires careful monitoring due to increased risks of renal failure and hypotension.
- Other names
- captopril + frusemide
02
Targets
ACE (Angiotensin Converting Enzyme)NKCC2 (Sodium-potassium-chloride cotransporter 2)NKCC (Sodium-potassium-chloride cotransporter)
Beyond the preview
Go deeper on captopril + furosemide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on captopril + furosemide.